Our Company
Innovative Cellular Therapeutics

Our mission is to develop innovative cellular therapies to transform cancer treatment worldwide

Innovative Cellular Therapeutics (ICT) is a clinical stage biotechnology company focused on the development of cellular immunotherapies for the treatment of cancer. ICT has achieved promising preclinical and clinical results in late-stage leukemia and lymphoma with its next generation CAR-T constructs. ICT’s lead candidate in the U.S., ICTCAR014, is a next generation CD19-targeting CAR-T cell therapy that expresses a dominant negative PD-1 (dnPD-1) protein to block immunosuppression by cancer cells. ICTCAR014 is being developed for patients with relapsed or refractory non-Hodgkin lymphoma (NHL), including PD-L1 positive patients. ICT’s lead candidate in China, ICTCAR003, is a CD19-targeting CAR-T cell therapy for the treatment of B-cell acute lymphoblastic leukemia. The Company also has a broad pipeline of CAR-T candidates targeting solid tumors.

Corporate Milestones

ICT has evolved into a fully integrated, international CAR-T biotechnology company with world-class capabilities.


IND cleared by U.S. FDA for ICTCAR014 (dnPD-1 CD19 CAR-T)


Presentation of ICTCAR014 (dnPD-1 CD19 CAR-T) data at SITC


Pre-IND meeting with U.S. FDA for ICTCAR014 (dnPD-1 CD19 CAR-T)


IND cleared by China FDA for ICTCAR003 (CD19 CAR-T)


U.S. HQ office opens in Maryland


ICTCAR003 (CD19 CAR-T) IND submission with China FDA


Series B initiated


Completed IRB-approved trial in 39 r/r ALL patients, with 85% CR and 80% MRD negative


Initiated IRB-approved NHL CAR-T trial in humans


Initiated IRB-approved ALL CAR-T trial in humans


Initiated CAR-T preclinical study


ICT founded in Shanghai with ES/iPS cell and gene editing platform